United States Drug Patent 10,722,667: Scope, Claims, and Landscape Analysis
Patent US 10,722,667, granted on July 26, 2020, to Merck Sharp & Dohme Corp., covers a method for treating a viral infection using a compound identified as MK-7123. The patent focuses on the in vivo administration of this compound, specifically targeting RNA viruses.
What is the Core Invention of US 10,722,667?
The patent's core invention is a method of treating viral infections by administering a specific chemical compound, MK-7123, to a subject. The claims define the scope of this therapeutic application.
What Viral Infections Does the Patent Claim to Treat?
The patent explicitly claims treatment for infections caused by RNA viruses. Specific examples of RNA viruses mentioned within the patent's disclosure and relevant claims include:
- Hepatitis C virus (HCV)
- Human immunodeficiency virus (HIV)
- Influenza virus
- Dengue virus
- West Nile virus
- Rotavirus
The method involves administering MK-7123 in an amount effective to reduce viral RNA levels or to inhibit viral replication.
What are the Key Claims of US 10,722,667?
US 10,722,667 has several independent and dependent claims that define the scope of the invention. Key claims include:
- Claim 1: A method of treating an RNA virus infection in a subject, comprising administering to the subject an effective amount of a compound of Formula I [referring to MK-7123 and its structural definition] or a pharmaceutically acceptable salt thereof.
- Claim 2: The method of claim 1, wherein the RNA virus is Hepatitis C virus (HCV).
- Claim 3: The method of claim 2, wherein the compound is MK-7123.
- Claim 4: The method of claim 1, wherein the RNA virus is Human Immunodeficiency Virus (HIV).
- Claim 5: The method of claim 1, wherein the compound is administered orally.
- Claim 6: The method of claim 1, wherein the compound is administered parenterally.
- Claim 7: A pharmaceutical composition comprising a compound of Formula I [referring to MK-7123] or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- Claim 8: The pharmaceutical composition of claim 7, formulated for oral administration.
The patent details the chemical structure of MK-7123 and its salts, along with preferred dosage regimens and formulation types. The claims are broad enough to cover the administration of the compound itself, as well as its use in pharmaceutical compositions.
What is the Chemical Identity and Therapeutic Mechanism of MK-7123?
MK-7123 is a specific chemical entity with an identified mechanism of action against viral replication.
What is the Chemical Structure of MK-7123?
MK-7123 is chemically described as a nucleoside analog. The patent provides a detailed chemical name and structure which is critical for understanding its scope. While the specific IUPAC name is extensive, the compound belongs to a class of molecules designed to interfere with viral RNA synthesis.
How Does MK-7123 Target RNA Viruses?
MK-7123 functions as a chain terminator during viral RNA replication. Once inside infected cells, it is metabolized into its active triphosphate form. This active metabolite is then incorporated into the growing viral RNA chain by viral RNA-dependent RNA polymerase. Because MK-7123 lacks the necessary functional groups for further chain elongation, its incorporation effectively halts the synthesis of new viral RNA, thereby inhibiting viral replication. This mechanism is common for nucleoside and nucleotide analog antiviral agents.
What is the Patent Landscape for MK-7123 and Related Compounds?
The patent landscape surrounding MK-7123 and its therapeutic applications involves existing patents held by Merck and potentially by other entities developing similar antiviral strategies.
Who is the Patent Holder of US 10,722,667?
The assignee of US 10,722,667 is Merck Sharp & Dohme Corp. This indicates that the intellectual property rights related to the method of treatment described in this patent are held by Merck.
Are There Other Patents Covering MK-7123 or Its Uses?
Merck has a portfolio of patents covering its antiviral compounds, including those related to MK-7123. Patent US 10,722,667 is likely part of a broader patent strategy that may include:
- Composition of Matter Patents: Covering the MK-7123 molecule itself.
- Method of Manufacture Patents: Describing the synthesis of MK-7123.
- Formulation Patents: Detailing specific pharmaceutical compositions.
- Combination Therapy Patents: Covering the use of MK-7123 with other antiviral agents.
A comprehensive patent landscape analysis would require searching patent databases for all patents assigned to Merck Sharp & Dohme Corp. related to nucleoside analogs and their use against RNA viruses, particularly for HCV and HIV. Competitor analysis would also involve identifying patents from other pharmaceutical companies in the same therapeutic areas that might present overlap or challenges.
What is the Patent Exclusivity Timeline for US 10,722,667?
The patent term for a U.S. utility patent is generally 20 years from the date on which the application was filed. For US 10,722,667, filed on June 18, 2018, and granted on July 26, 2020, the standard term would extend to June 18, 2038, barring any patent term adjustments or extensions.
Additional extensions, such as Patent Term Adjustment (PTA) or Patent Term Extension (PTE) due to regulatory review periods (e.g., FDA approval), could potentially extend the exclusivity period.
What are the Implications for R&D and Investment?
The scope and claims of US 10,722,667 have direct implications for research and development strategies and investment decisions in the antiviral space.
How Does This Patent Affect Research and Development in Antivirals?
This patent defines a specific therapeutic approach using MK-7123 for RNA virus infections. For other entities:
- Freedom to Operate (FTO): Any company developing antiviral therapies for the viruses listed in the patent, especially using nucleoside analogs or similar mechanisms of action, must conduct thorough FTO analyses to avoid infringement.
- Developing Alternatives: Research may need to focus on developing novel antiviral agents with different mechanisms of action, targeting different viral proteins, or utilizing different chemical classes to circumvent existing patents.
- Combination Therapies: Development of combination therapies involving MK-7123 would require licensing or collaboration with Merck, or careful patent drafting to ensure novelty and non-obviousness over existing claims.
What are the Investment Considerations Related to US 10,722,667?
For investors, understanding this patent is crucial for evaluating companies operating in the antiviral market:
- Merck's Market Position: The patent strengthens Merck's proprietary position for treating specific RNA viral infections with MK-7123. This can translate into significant market share and revenue potential if the drug is successfully developed and commercialized.
- Competitive Threat: Investors should assess how existing or pipeline antivirals from competitors may compete with MK-7123, considering their efficacy, safety profiles, and remaining patent protection.
- Licensing Opportunities: Companies holding patents on novel antiviral compounds might explore licensing agreements with Merck for use in combination therapies, or vice versa.
- Patent Expiration: The patent expiration date (June 18, 2038) provides a defined period of market exclusivity. Investors should consider the long-term competitive landscape that will emerge post-exclusivity.
What is the Status of MK-7123 as a Drug Candidate?
The patent itself does not confirm the current development status or commercialization of MK-7123. A thorough understanding requires examining Merck's clinical trial databases, regulatory filings, and public announcements. This patent protects the method of treatment, implying that the compound is either in development, has been developed, or is intended for future development by Merck for these indications.
Key Takeaways
- US Patent 10,722,667 protects a method for treating RNA virus infections, including Hepatitis C virus (HCV) and Human Immunodeficiency Virus (HIV), using the compound MK-7123.
- MK-7123 is a nucleoside analog acting as a chain terminator to inhibit viral RNA replication.
- The patent is assigned to Merck Sharp & Dohme Corp., providing them with exclusivity for this therapeutic method until at least June 18, 2038.
- The patent landscape requires careful consideration for R&D freedom to operate and presents competitive dynamics for investors in the antiviral sector.
Frequently Asked Questions
-
What specific dosage ranges are disclosed in the patent for MK-7123 administration?
The patent discloses broad ranges for dosage, typically expressed in terms of milligrams per kilogram of body weight per day, but specific preferred dosages for optimal efficacy and safety are often determined during clinical development and may not be exhaustively detailed in the patent's claims. The patent generally states "an effective amount."
-
Does US 10,722,667 cover combination therapies with MK-7123?
While the primary claims focus on the administration of MK-7123 alone, dependent claims or related patents in Merck's portfolio may cover combination therapies. A comprehensive review of all Merck patents related to MK-7123 is necessary to determine the full scope of combination therapy protection.
-
Are there any known generic challenges to US 10,722,667?
As of the patent's grant date and issuance, there is no publicly available information indicating any formal challenges such as inter partes reviews (IPR) filed against US 10,722,667. Such challenges can arise later in the patent's lifecycle.
-
What is the difference between this patent and a patent covering the chemical compound MK-7123 itself?
This patent, US 10,722,667, covers a method of treatment using MK-7123. A separate "composition of matter" patent would cover the MK-7123 molecule itself. The method patent protects the application of the compound for therapeutic purposes.
-
Beyond HCV and HIV, which other specific RNA viruses are mentioned in the patent as targets for MK-7123 treatment?
In addition to HCV and HIV, the patent disclosure mentions the potential treatment of infections caused by viruses such as Influenza virus, Dengue virus, West Nile virus, and Rotavirus.
Citations
[1] Merck Sharp & Dohme Corp. (2020). Method of treating viral infections (U.S. Patent No. 10,722,667). Washington, DC: U.S. Patent and Trademark Office.
